Crucial FDA drug reviews expected to be slowed by job cuts

Plus: National public health group calls for RFK Jr. to resign, citing 'complete disregard for science'

April 11, 2025 Check out STAT+

Sponsored By

Molly Ferguson for STAT Opinion: The National Cancer Institute's Investigational New Drug program is imperative for public good The former chief of the National Cancer Institute's Investigational Drug Branch responds to an op-ed criticizing the program. By Jeffrey Moscow National public health group calls for RFK Jr. to resign, citing 'complete disregard for science' Georges Benjamin, executive director of the American Public Health Association, said Kennedy had shown "complete disregard for science" as health secretary. By Elizabeth Cooney U.S. maternal mortality rate increased 27% over five years, NIH study finds Study finds U.S. maternal mortality increased from 2018 to 2022, calls issue "urgent public health priority." Report comes as research is cut. By Anil Oza Adobe STAT+ | Crucial FDA drug reviews expected to be slowed by job cuts A former top FDA official said it's only a matter of time before the chaos at the agency starts to impact drug reviews.  By Lizzy Lawrence, Matthew Herper, and Elaine Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser